By Bhanvi Satija LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated ...

The trial is tied to a post-marketing commitment that FDA Commissioner Martin Makary put in place last year for all approved ...

COVID-19 partners Pfizer and BioNTech have been unable to recruit healthy adults aged 50 to 64 fast enough to deliver ...

Pfizer BioNTech halt COVID vaccine study in adults 50-64 due to slow enrollment, citing inability to generate relevant postmarketing data.

Pfizer (PFE) stock and BioNTech (BNTX) stock are in focus as a large U.S. trial for the companies' updated COVID-19 vaccine ...

The move comes as COVID vaccine ‌makers grapple ‌with pushback from the U.S. administration and weak U.S. demand for the ...

Moderna is suing Pfizer and BioNTech for infringing patents central to Moderna's mRNA technology platform used to develop the COVID vaccine, the company said in a press release Friday. A widely ...

BioNTech will wind up its vaccine manufacturing plant in Singapore by February 2027 after a strategic review. Read more at ...

The Trump administration has also pushed back against Covid vaccine recommendations, and the FDA toughened its requirements ...

Pfizer and BioNTech have stopped their large U.S. COVID-19 vaccine trial in adults aged 50 to 64, citing insufficient ...